UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934

Filed by the Registrant ☐ Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

☐ Definitive Proxy Statement

☐ Definitive Additional Materials

☐ Soliciting Material under §240.14a-12

AURINIA PHARMACEUTICALS INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

☐ No fee required.

☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

☐ Fee paid previously with preliminary materials.

☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

Aurinia™

Dear Fellow Shareholders,

We set high goals for our company in 2021 to realize our mission of transforming people's lives by delivering therapeutics that change the course of rare, autoimmune and kidney related diseases. I believe we exceeded our expectations and have built a solid foundation for future growth.

Key Accomplishments

Aurinia Key Milestones

- ✓ Advancing from single-asset company to a diversified, fully-integrated biopharmaceutical organization with global reach and scale
- ✓ Established leader in care for adult patients with active LN with three years of pivotal trial results and long-term safety data
- ✓ Focused on voclosporin commercial strategy for LN
- ✓ Acquisitions of preclinical compounds AUR200 and AUR300 bolster innovation pipeline
- ✓ Strong balance sheet to fund current initiatives and FDA-related post approval commitments



Establishing a Leadership Position in Lupus Nephritis

This past year we made strong progress toward making LUPKYNIS the standard of care for adult patients suffering from active lupus nephritis (LN) through the achievement of many corporate milestones:

- We received US FDA approval for LUPKYNIS after close of business on Friday, January 22nd, 2021, and were able to launch our first commercial product the following business day, which speaks to the extraordinary launch readiness of our team.
- Since the launch of LUPKYNIS, we have secured a total of 1,773 patient start forms as of February 25, 2022 – which helps validate the product's awareness, adoption and access amongst healthcare professionals and the community at large.
- We achieved $45.6 million annual revenue for the full year, which was in line with our revenue guidance initially provided on August 5, 2021.
- Together with our partner Otsuka, we filed a marketing authorization application (MAA) for the approval of voclosporin by the European Medicines Agency (EMA). This was a key step toward globalizing our products and enabling access for patients beyond the US.
- The Lancet, an international peer-reviewed medical journal, published the LUPKYNIS pivotal registrational study in May 2021.
- In December 2021 we presented top-line data from the AURORA 2 two-year continuation study, the longest LN study to date, demonstrating a favorable risk/benefit profile for voclosporin over a three-year period, with safety comparable to AURORA 1, and sustained efficacy.

"We received US FDA approval for LUPKYNIS after close of business on Friday, January 22nd, 2021, and were able to launch our first commercial product the following business day, which speaks to the extraordinary launch readiness of our team"

Creating a Strong Pipeline

In addition to the progress we made with LUPKYNIS, we bolstered our pipeline with two new innovative programs. We announced the acquisition of two novel, preclinical compounds: AUR200 and AUR300. Adding these assets, as well as building out our capabilities in research, translational medicine and process development, has helped us advance our goal from being a single-asset company towards a diversified, fully integrated biopharmaceutical organization.

We also significantly improved our capital position by ending the year with cash and cash equivalents of $466.1 million, which provides us with the necessary financial resources to fund our current objectives, of fueling our commercial launch, funding our growing pipeline, meeting our FDA-related post-approval commitments and executing on our business development strategy.

Our achievements related to the approval and launch of LUPKYNIS, along with strengthening our pipeline, helped drive our share performance and outpace the major biotech stock indexes over the last 1 and 3-year time periods, respectively.

Engaging with our Shareholders and Maintaining High Standards of Corporate Governance

Throughout the course of the approval and launch process this past year, our management team made a focused effort to engage with our shareholders to ensure they were properly apprised of our corporate strategy and recent developments, and to hear our investors' views on matters important to the business. Overall, we were pleased by the support of our investor-base and the engagement regarding our company's progress on multiple fronts over the past year, as well as future growth initiatives and other topics of interest, such as our approach to Environmental, Social and Governance matters.

Responsibility also means ensuring high standards of corporate governance. Aurinia has an independent, diverse and highly qualified Board that continually seeks to raise the bar with regards to governance, diversity and expertise. In June 2021, we appointed Dr. Brinda Balakrishnan to the Board of Directors, who brings a wealth of experience in medicine, biotech business development and the rare disease

"Our achievements related to the launch of LUPKYNIS and the strengthening of our pipeline helped drive our share performance appreciation against biotech stock indexes during 2021"

sector. We expect Dr. Balakrishnan's expertise and counsel to be extremely valuable as we work to change the course of LN and other autoimmune diseases.

Closing Remarks

All of these initiatives were undertaken against the backdrop of COVID-19, which affected the healthcare industry and disproportionately our business due to the immune compromised nature of our patients. Despite this challenge and others, our employees rose to the occasion, and we believe we have exceeded our high expectations. Both management and the Board are extremely proud and honored to work with such a capable and skilled group of employees.

In closing, I would like to thank our shareholders. You have trusted us with your capital, and we do not take that for granted. We look forward to continuing to build a sustainable, value-creating bio-pharmaceutical company.

We encourage you to vote at our annual general meeting of shareholders and we thank you for your continued support.

Sincerely,

Peter Greenleaf
Director, President and Chief Executive Officer